HC Wainwright Has Positive Outlook of Genmab A/S Q3 Earnings

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Stock analysts at HC Wainwright upped their Q3 2026 earnings per share estimates for Genmab A/S in a research note issued to investors on Monday, September 14th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.49 per share for the quarter, up from their previous forecast of $0.37. HC Wainwright currently has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.17 per share. HC Wainwright also issued estimates for Genmab A/S’s Q4 2026 earnings at $0.44 EPS and FY2026 earnings at $1.48 EPS.

A number of other equities research analysts have also recently commented on the company. Weiss Ratings raised Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, September 1st. TD Cowen upgraded shares of Genmab A/S from a “hold” rating to a “buy” rating and boosted their target price for the company from $32.00 to $43.00 in a research note on Wednesday, July 22nd. Guggenheim upped their price target on shares of Genmab A/S from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Truist Financial assumed coverage on shares of Genmab A/S in a research report on Wednesday, May 27th. They set a “buy” rating and a $40.00 target price for the company. Finally, New Street Research set a $43.00 target price on shares of Genmab A/S in a report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, Genmab A/S has a consensus rating of “Moderate Buy” and a consensus price target of $39.50.

Genmab A/S Price Performance

Shares of NASDAQ GMAB opened at $34.15 on Wednesday. The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.44 and a current ratio of 2.46. The company has a market capitalization of $21.30 billion, a price-to-earnings ratio of 26.89, a P/E/G ratio of 1.84 and a beta of 0.84. The company has a 50 day simple moving average of $31.19 and a two-hundred day simple moving average of $28.32. Genmab A/S has a fifty-two week low of $23.62 and a fifty-two week high of $35.43.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.17. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.12 billion. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Arrowstreet Capital Limited Partnership boosted its position in shares of Genmab A/S by 36.6% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock valued at $153,324,000 after acquiring an additional 1,334,919 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Genmab A/S by 26.4% during the 1st quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock valued at $118,442,000 after buying an additional 921,700 shares in the last quarter. First Trust Advisors LP lifted its holdings in Genmab A/S by 84.3% during the 1st quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock valued at $66,038,000 after buying an additional 1,126,069 shares in the last quarter. Cibc World Market Inc. boosted its position in Genmab A/S by 31.2% in the 4th quarter. Cibc World Market Inc. now owns 367,282 shares of the company’s stock valued at $11,312,000 after buying an additional 87,350 shares during the period. Finally, Quantinno Capital Management LP boosted its position in Genmab A/S by 14.4% in the 1st quarter. Quantinno Capital Management LP now owns 282,498 shares of the company’s stock valued at $7,579,000 after buying an additional 35,588 shares during the period. Institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering, developing and commercializing differentiated antibody-based medicines. The company’s research platforms include technologies designed to create human antibodies and bispecific antibodies that engage the immune system to target cancer and other serious diseases.

Genmab’s products and partnered medicines include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; Kesimpta (ofatumumab) for multiple sclerosis, developed with Novartis; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Pfizer.